Oxurion Publishes First Half 2023 Results
September 29, 2023 13:00 ET
|
Oxurion NV
Regulated Information Leuven, BELGIUM, Boston, MA, US – September 29, 2023 – 7.00 PM CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next-generation standard of...
Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC
September 27, 2023 13:00 ET
|
Oxurion NV
Regulated Information Leuven, BELGIUM, Boston, MA, US – September 27, 2023 – 7.00 PM CET Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard of care...
Oxurion Receives First EUR 1 Million under Amended Atlas Funding Program
September 18, 2023 02:04 ET
|
Oxurion NV
EUR 3.5 Million in Unconditional Funding Allowing Company to Achieve Topline Data from KALAHARI Trial Leuven, BELGIUM, Boston, MA, US – September 18, 2023 – 8 am CET – Oxurion NV (Euronext Brussels:...
Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas
September 18, 2023 02:02 ET
|
Oxurion NV
Regulated Information - Denominator Atlas Special Opportunities, LLC has converted 6 convertible bonds in Oxurion resulting in a EUR 150,000 capital increase. This is part of Atlas Special...
Oxurion Receives Transparency Notifications from Atlas Special Opportunities LLC
September 18, 2023 02:00 ET
|
Oxurion NV
Regulated Information Leuven, BELGIUM, Boston, MA, US – September 18, 2023 – 8.00 AM CET Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard of care...
Oxurion Announces Key Amendments to Atlas and Kreos/Pontifax Agreements Enabling KALAHARI Trial to Progress to Topline Results in 2023
September 11, 2023 02:00 ET
|
Oxurion NV
Regulated Information – Inside Information Waives Key Conditions for Up to €3.5 Million in Atlas FundingReduces Cash Covenant and Total Debt for Kreos/Pontifax Loan Leuven, BELGIUM, Boston,...
Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas
September 07, 2023 13:00 ET
|
Oxurion NV
Regulated Information - Denominator Atlas Special Opportunities, LLC has converted 6 convertible bonds in Oxurion resulting in a EUR 150,000 capital increase. This is part of Atlas Special...
Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC
September 01, 2023 13:00 ET
|
Oxurion NV
Regulated Information Leuven, BELGIUM, Boston, MA, US – September 1, 2023 – 7.00 PM CET Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard of care...
Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas
September 01, 2023 13:00 ET
|
Oxurion NV
Regulated Information - Denominator Atlas Special Opportunities, LLC has converted 10 convertible bonds in Oxurion resulting in a EUR 250,000 capital increase. This is part of Atlas Special...
Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas
August 25, 2023 16:00 ET
|
Oxurion NV
Regulated Information - Denominator Atlas Special Opportunities, LLC has converted 8 convertible bonds in Oxurion resulting in a EUR 200,000 capital increase. This is part of Atlas Special...